Showing results (1221-1230 of 1,427) with videos related to

Sort By:
Pageof 143
Cells|March 1, 2019
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open QuestionsMarina Bagnoli, Ting Yan Shi, Charlie Gourley, et al.
Environmental Research|June 14, 2024
Modulating temperature for Cu2ZnSnS4 (CZTS) synthesis via hot injection method and studying the photocatalytic efficiencies for the degradation of rhodamine 6G and methylene blue pollutantsValentina Nava Murillo, Darshana Rajput, J Manríquez, et al.
Nature Communications|March 16, 2023
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinomaAinhoa Madariaga, Swati Garg, Nairi Tchrakian, et al.
Emerging Infectious Diseases|January 20, 2018
Development of a Pediatric Ebola Predictive Score, Sierra Leone1Felicity Fitzgerald, Kevin Wing, Asad Naveed, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 18, 2017
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancerMadeleine T King, Martin R Stockler, Rachel L O'Connell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2020
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition ProgressionStephanie Lheureux, Ana Oaknin, Swati Garg, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2021
Reanalysis of eMERGE phase III sequence variants in 10,500 participants and infrastructure to support the automated return of knowledge updatesHana Zouk, Wanfeng Yu, Andrea Oza, et al.
The Lancet. Oncology|July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialEric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
Journal of Oncology Practice|September 25, 2019
Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic CancerYeh Chen Lee, Nazlin Jivraj, Lisa Wang, et al.
Molecular Cancer Therapeutics|July 24, 2023
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and LymphomaErika P Hamilton, Judy S Wang, Amit M Oza, et al.
Pageof 143